Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the roche COBAS ampliprep/COBAS TaqMan HIV-1 Version 1.0 viral load test

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 4, 2010, Pages 442-444

  Willig, James H ^a   Nevin, Christa R ^a   Raper, James L ^a   Saag, Michael S ^a   Mugavero, Michael J ^a   Willig, Amanda L ^b   Burkhardt, Jeffrey H ^b   Schumacher, Joseph E ^c   Johnson, Victoria A ^d  

^a Division of Infectious Diseases   (United States)

^b Department of Medicine ^*  (United States)

^c Division of Preventive Medicine   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

COST BENEFIT ANALYSIS; GENOTYPE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VEIN PUNCTURE; VIRUS LOAD; ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD; COST OF ILLNESS; ECONOMICS; GENETICS; METHODOLOGY; VIREMIA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; COST OF ILLNESS; HIV-1; HUMANS; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 77955485827     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181d01d1d     Document Type: Letter

References (12)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretrovirals Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services; 2008:1-139.
2. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immuno-logic markers to clinical outcomes after nucleo-side therapy in HIV-infected adults with 200 to 500 CD4 cells per cublic millimeter. N Engl J Med. 1996;335:1091-1098.
3. O'Brien WA, Hartigan PM, Daar ES, et al. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med. 1997;126:939-945.
4. Lin HJ, Myers LE, Yen-Lieberman B, et al. Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis. 1994;170:553-562.
5. Katsoulidou A, Petrodaskalaki M, Sypsa V, et al. Evaluation of the clinical sensitivity for the quantification of human immunodeficiency virus type 1 RNA in plasma: Comparison of the new COBAS TaqMan HIV-1 with thre current HIV-RNA assays-LCx HIV RNA quantitative, VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 Monitor v1.5. J Virol Methods. 2006;131:18-174.
6. Oliver AR, Pereira SF, Clark DA. Comparative evaluation of the automated Roche TaqMan real-time quantitative human immunodeficiency virus type 1 RNA PCR assay and the Roche AMPLICOR version 1.5 conventional PCR assay. J Clin Microbiol. 2007;45:3616-3619.
7. Damond F, Roquebert B, Benard A, et al. Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays. J Clin Micro-biol. 2007;45:3436-3438.
8. Gatanaga H, Tsukada K, Honda H, et al. Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor. Clin Infect Dis. 2009;48:260-262.
9. Lima V, Harrigan R, Montaner JS. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr. 2009;51:3-6.
10. Smit E, Bhattacharya S, Osman H, et al. Increased frequency of HIV-1 viral load blip rate observed after switching from Roche Cobas Amplicor to Cobas Taqman assay. J Acquir Immune Defic Syndr. 2009;51: 364-365.
11. Willig JH, Westfall AO, Allison J, et al. Nucleoside reverse- transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record era. Clin Infect Dis. 2007;45:658-661.
12. Peterson ML, Van Der Laan MJ, Napravnik S, et al. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS. 2008;22:2097-2106.